JAK1 and colorectal carcinoma: Our research suggests that bufalin can inhibit the JAK1‐STAT3 signaling pathway by inhibiting the expression of SRC‐1, thereby down‐regulating the expression of PD‐L1, inhibiting the immune escape of CRC, and ultimately exerting antitumor effects.